[1] Corrado RE, Lee D, Lucero DE, et al. Burden of adult community-acquired, health-care-associated, hospital-acquired, and ventilator-associated Pneumonia: New York City, 2010 to 2014. Chest, 2017; 152, 930−42. doi:  10.1016/j.chest.2017.04.162
[2] Ticona JH, Zaccone VM, McFarlane IM. Community-acquired Pneumonia: A focused review. Am J Med Case Rep, 2021; 9, 45−52.
[3] Yin YY, Zhao CJ, Li HN, et al. Clinical and microbiological characteristics of adults with hospital-acquired pneumonia: a 10-year prospective observational study in China. Eur J Clin Microbiol Infect Dis, 2021; 40, 683−90. doi:  10.1007/s10096-020-04046-9
[4] Guo YL, Song GH, Sun ML, et al. Prevalence and therapies of antibiotic-resistance in Staphylococcus aureus. Front Cell Infect Microbiol, 2020; 10, 107. doi:  10.3389/fcimb.2020.00107
[5] Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis, 2011; 52, e18−55. doi:  10.1093/cid/ciq146
[6] Ye ZK, Chen YL, Chen K, et al. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese pharmacological society. J Antimicrob Chemother, 2016; 71, 3020−5. doi:  10.1093/jac/dkw254
[7] Park SJ, Lim NR, Park HJ, et al. Evaluation of risk factors for vancomycin-induced nephrotoxicity. Int J Clin Pharm, 2018; 40, 1328−34. doi:  10.1007/s11096-018-0634-8
[8] Perin N, Roger C, Marin G, et al. Vancomycin Serum Concentration after 48 h of administration: A 3-years survey in an intensive care unit. Antibiotics (Basel), 2020; 9, 793. doi:  10.3390/antibiotics9110793
[9] Zhou QT, Zhao FF, Wang M. An individualized administration model of vancomycin in elderly patients with sepsis and factors influencing augmented renal clearance. J Clin Pharm Ther, 2021; 46, 447−53. doi:  10.1111/jcpt.13304
[10] Masich AM, Kalaria SN, Gonzales JP, et al. Vancomycin pharmacokinetics in obese patients with sepsis or septic shock. Pharmacotherapy, 2020; 40, 211−20. doi:  10.1002/phar.2367
[11] Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired Pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med, 2019; 200, e45−67. doi:  10.1164/rccm.201908-1581ST
[12] Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated Pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis, 2016; 63, e61−e111. doi:  10.1093/cid/ciw353
[13] Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron, 1976; 16, 31−41. doi:  10.1159/000180580
[14] Ad-Hoc Working Group of ERBP, Fliser D, Laville M, et al. A European renal best practice (ERBP) position statement on the kidney disease improving global outcomes (KDIGO) clinical practice guidelines on acute kidney injury: Part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant, 2012; 27, 4263−72. doi:  10.1093/ndt/gfs375
[15] Ueda T, Takesue Y, Nakajima K, et al. Validation of vancomycin area under the concentration-time curve estimation by the Bayesian approach using one-point samples for predicting clinical outcomes in patients with methicillin-resistant Staphylococcus aureus infections. Antibiotics (Basel), 2022; 11, 96. doi:  10.3390/antibiotics11010096
[16] Mogle BT, Steele JM, Seabury RW, et al. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents, 2018; 52, 805−10. doi:  10.1016/j.ijantimicag.2018.08.024
[17] Álvarez R, Cortés LEL, Molina J, et al. Optimizing the clinical use of vancomycin. Antimicrob Agents Chemother, 2016; 60, 2601−9. doi:  10.1128/AAC.03147-14
[18] Wang YC, Dai N, Wei W, et al. Outcomes and nephrotoxicity associated with vancomycin treatment in patients 80 years and older. Clin Interv Aging, 2021; 16, 1023−35. doi:  10.2147/CIA.S308878
[19] Blot S, Koulenti D, Akova M, et al. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Crit Care, 2014; 18, R99. doi:  10.1186/cc13874
[20] Molina KC, Hall ST, Barletta JF, et al. Utilization of augmented renal clearance in trauma intensive care scoring system to improve vancomycin dosing in trauma patients at risk for augmented renal clearance. Surg Infect (Larchmt), 2020; 21, 43−7. doi:  10.1089/sur.2019.026
[21] Kosmisky DE, Griffiths CL, Templin MA, et al. Evaluation of a new vancomycin dosing protocol in morbidly obese patients. Hosp Pharm, 2015; 50, 789−97. doi:  10.1310/hpj5009-789
[22] Kondo M, Nakagawa S, Orii S, et al. Association of initial trough concentrations of vancomycin with outcomes in pediatric patients with gram-positive bacterial infection. Biol Pharm Bull, 2020; 43, 1463−8. doi:  10.1248/bpb.b19-01003
[23] Truong J, Smith SR, Veillette JJ, et al. Individualized pharmacokinetic dosing of vancomycin reduces time to therapeutic trough concentrations in critically Ill patients. J Clin Pharmacol, 2018; 58, 1123−30. doi:  10.1002/jcph.1273
[24] Tang L, Ding XY, Duan LF, et al. A regression model to predict augmented renal clearance in critically Ill obstetric patients and effects on vancomycin treatment. Front Pharmacol, 2021; 12, 622948. doi:  10.3389/fphar.2021.622948
[25] Qian XD, Du GT, Weng CM, et al. Evaluation of the variability and safety of serum trough concentrations of vancomycin in patients admitted to the intensive care unit. Int J Infect Dis, 2017; 60, 17−22. doi:  10.1016/j.ijid.2017.04.018
[26] Zhang XW, Wang DH. The characteristics and impact indicator of vancomycin pharmacokinetics in cancer patients complicated with severe pneumonia. J Infect Chemother, 2020; 26, 492−7. doi:  10.1016/j.jiac.2019.12.019
[27] He J, Mao EQ, Feng J, et al. The pharmacokinetics of vancomycin in patients with severe acute pancreatitis. Eur J Clin Pharmacol, 2016; 72, 697−702. doi:  10.1007/s00228-016-2018-0
[28] Hirai T, Hanada K, Iwamoto T, et al. Involvement of the effect of renal hypoperfusion medications on vancomycin trough concentration: A secondary analysis using a retrospective observational data. Basic Clin Pharmacol Toxicol, 2021; 129, 376−84. doi:  10.1111/bcpt.13646
[29] Chuma M, Makishima M, Imai T, et al. Duration of systemic inflammatory response syndrome influences serum vancomycin concentration in patients with sepsis. Clin Ther, 2016; 38, 2598−609. doi:  10.1016/j.clinthera.2016.10.009
[30] Chen CY, Xu P, Xu T, et al. Influence of cerebrospinal fluid drainage and other variables on the plasma vancomycin trough levels in postoperative neurosurgical patients. Br J Neurosurg, 2021; 35, 133−8. doi:  10.1080/02688697.2020.1769023